2Городская клиническая больница №5 Департамента здравоохранения г. Москвы, Россия 3 ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России, Москва, Россия Распространенность инсулином составляет 1-3 случая на один миллион населения в год, из которых в 4-14% случаев опухоль является злокачественной. Увеличение массы тела является одним из проявлений заболевания, нередко приводя к морбидному ожирению с показаниями для оперативного лечения. Представленный клинический случай, демонстрирует успешное лечение пациента с низким функциональным статусом на фоне злокачественной инсулиномы с манифестацией рефрактерного гипогликемического синдрома после проведения билиопанкреатического шунтирования с продольной резекцией желудка по поводу морбидного ожирения.КЛЮЧЕВЫЕ СЛОВА: гипогликемический синдром, злокачественная инсулинома, морбидное ожирение, бариатрическая хирургия, билиопанкреатическое шунтирование, клинический случай.The prevalence of insulinomas is 1-3 cases per million population per year of which 4-14% tumor is malignant. Weight gain is one of the symptoms of the disease, often resulting in morbid obesity with indications for surgical treatment. The presented clinical case demonstrates the successful treatment of malignant insulinoma with the manifestation of hypoglycemic syndrome after carrying out biliopancreatic bypass with longitudinal gastrectomy for morbid obesity. TO CITE THIS ARTICLE:Maloletkina ES, Gurova OYu, Fadeev VV, Egorov VI, Petrov RV, Beltsevich DG. Case of insulinoma detected in a patient after bariatric operation for morbid obesity. Obesity and metabolism. 2019;16(1):74-80.
Introduction. In type 2 diabetes mellitus, an inevitable decrease in the secretion of β-cells of the pancreas occurs, which requires the initiation of insulin therapy. Currently, there have been no studies evaluating the features of insulin therapy in patients with diabetes type 2 and morbid obesity.Objective. To compare the effectiveness of different insulin therapy regimens in patients with type 2 diabetes mellitus and morbid obesity. Materials and methods. 140 patients with diabetes type 2 and morbid obesity were included in a 24-week prospective, non-blinded, randomized clinical study. The patients were divided into 4 groups: 1 – received basic-bolus insulin therapy in combination with metformin (n = 40); 2 – used prandial insulin in combination with metformin (n = 40); 3 – basal insulin in combination with empagliflozin and metformin (n = 30); 4 – received prandial insulin in combination with empagliflozin and metformin (n = 30). Initially, after 12 and 24 weeks, the level of HbA1c, fasting plasma glucose and during the day, body weight, daily insulin doses, frequency of hypoglycemia, and albumin in daily urine were assessed.Results. After 24 weeks of treatment, there was no statistically significant difference in the achieved HbA1c level between the groups (p = 0.65); in groups 3 and 4, there was a statistically significant decrease in body weight, daily doses of insulin and frequency of hypoglycemia compared to the first and second treatment groups (p = 0.029, p < 0.001 and p < 0,001, respectively); also registered a decrease in albumin in daily urine by 27% during the study period compared with the first and second treatment groups (p = 0.044).Conclusions. Administration of iSGLT-2 in combination with both basal and prandial insulin in patients with diabetes type 2 and morbid obesity has advantages over the basic-bolus regimen and the regimen of multiple prandial injections, despite the comparable efficacy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.